---
figid: PMC8889569__fimmu-13-768606-g004
figtitle: 'Phosphatidylcholine-Derived Lipid Mediators: The Crosstalk Between Cancer
  Cells and Immune Cells'
organisms:
- Mus musculus
- Rattus norvegicus
- Cavia porcellus
- Cricetulus griseus
- Homo sapiens
- Candida dubliniensis
organisms_ner:
- Homo sapiens
- Mus musculus
- Rattus norvegicus
- Cricetulus griseus
- Cavia porcellus
- Drosophila melanogaster
- Danio rerio
pmcid: PMC8889569
filename: fimmu-13-768606-g004.jpg
figlink: /pmc/articles/PMC8889569/figure/f4/
number: F4
caption: Lipid mediators generated by phosphatidylcholine (PtdCho) turnover that contribute
  to therapy resistance. PtdCho is hydrolyzed by phospholipase A2 (PLA2), resulting
  in the production of lysophosphatidylcholine (lyso-PC) and arachidonic acid (AA).
  The COX2 enzymes catalyze the conversion of AA to prostaglandin E2 (PGE2), and lyso-PC
  acetyltransferases (LPCATs) convert lyso-PC into platelet-activating factor (PAF).
  Alternatively, lyso-PC can be hydrolyzed by autotaxin (ATX) and generate lysophosphatidic
  acid (LPA). These three lipid mediators, PGE2, PAF, and LPA, are secreted and bind
  to their cognate receptors EP1-4, PAFR, and LPAR1-6, respectively, promoting cancer
  cell proliferation, survival, and migration. PtdCho is also hydrolyzed by phosphatidylcholine
  phospholipase C (PC-PLC) and D (PC-PLD), generating diacylglycerol (DAG) and phosphatidic
  acid (PA). DAG activates the protein kinase C (PKC) pathway, and PA is crucial for
  mTOR activity, promoting cancer cell proliferation and survival. All these catabolic
  products of PtdCho have been involved in therapy resistance. Created with BioRender.com.
papertitle: 'Phosphatidylcholine-Derived Lipid Mediators: The Crosstalk Between Cancer
  Cells and Immune Cells.'
reftext: Renata de Freitas Saito, et al. Front Immunol. 2022;13:768606.
year: '2022'
doi: 10.3389/fimmu.2022.768606
journal_title: Frontiers in Immunology
journal_nlm_ta: Front Immunol
publisher_name: Frontiers Media S.A.
keywords: lipid metabolism | phosphatidylcholine | lipid mediators | immunoregulation
  | immune microenvironment | cancer drug resistance
automl_pathway: 0.9495878
figid_alias: PMC8889569__F4
figtype: Figure
redirect_from: /figures/PMC8889569__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8889569__fimmu-13-768606-g004.html
  '@type': Dataset
  description: Lipid mediators generated by phosphatidylcholine (PtdCho) turnover
    that contribute to therapy resistance. PtdCho is hydrolyzed by phospholipase A2
    (PLA2), resulting in the production of lysophosphatidylcholine (lyso-PC) and arachidonic
    acid (AA). The COX2 enzymes catalyze the conversion of AA to prostaglandin E2
    (PGE2), and lyso-PC acetyltransferases (LPCATs) convert lyso-PC into platelet-activating
    factor (PAF). Alternatively, lyso-PC can be hydrolyzed by autotaxin (ATX) and
    generate lysophosphatidic acid (LPA). These three lipid mediators, PGE2, PAF,
    and LPA, are secreted and bind to their cognate receptors EP1-4, PAFR, and LPAR1-6,
    respectively, promoting cancer cell proliferation, survival, and migration. PtdCho
    is also hydrolyzed by phosphatidylcholine phospholipase C (PC-PLC) and D (PC-PLD),
    generating diacylglycerol (DAG) and phosphatidic acid (PA). DAG activates the
    protein kinase C (PKC) pathway, and PA is crucial for mTOR activity, promoting
    cancer cell proliferation and survival. All these catabolic products of PtdCho
    have been involved in therapy resistance. Created with BioRender.com.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - COX8A
  - CPOX
  - COX5A
  - COX5B
  - COX6C
  - COX7C
  - .na.character
  - COX4I1
  - COX4I2
  - COX6A1
  - COX6A2
  - COX6B1
  - COX6B2
  - COX7A1
  - COX7A2
  - COX7B
  - COX7B2
  - COX8C
  - PTGER1
  - PTGER4
  - PTGER2
  - SPAG11B
  - PTGER3
  - PLA2G1B
  - PLA2G2A
  - PLA2G6
  - PLA2G3
  - PLA2G5
  - PLA2G7
  - PLA2G10
  - PLA2G12A
  - PLA2G12B
  - PLA2G2C
  - PLA2G2D
  - PLA2G2E
  - PLA2G2F
  - PLA2G4A
  - PLA2G4C
  - PLA2G4D
  - LPCAT3
  - LPCAT1
  - MBOAT2
  - PCLAF
  - PTAFR
  - ENPP2
  - SMG1
  - DMBX1
  - LPA
  - LPAR1
  - LPAR3
  - LPAR5
  - LPAR6
  - LPAR4
  - LPAR2
  - MTOR
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - H2-Aa
  - Cox4i1
  - Ptger1
  - Lypd8l
  - Ptger4
  - Ptger2
  - Ptger3
  - Pla2g2a
  - Pla2g5
  - Lpcat3
  - Lpcat1
  - Paf
  - Pclaf
  - Ptafr
  - Gpr135
  - Enpp2
  - Dmbx1
  - Lpar1
  - Lpar3
  - Lpar5
  - Lpar6
  - Lpar4
  - Lpar2
  - Mtor
  - Ubap2l
  - Mboat2
  - Prkcg
  - Prkca
  - aa
  - COX4
  - CG42237
  - LPCAT
  - atms
  - atx
  - Pld
  - Pa
  - Tor
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - enpp2
  - lpar1
  - lpar3
  - lpar6
  - lpar6a
  - lpar4
  - mtor
---
